Baidu
map

PD-L1单抗Imfinzi在日本获批,治疗广泛期小细胞肺癌

2020-08-22 MedSci原创 MedSci原创

Imfinzi是人源化的PD-L1单抗,可与PD-L1结合并阻断PD-L1与PD-1和CD80的相互作用,从而对抗肿瘤的免疫逃避并释放对免疫反应的抑制作用。

阿斯利康的PD-L1单抗Imfinzi(durvalumab)在日本获批,与依托泊苷和一种铂类化疗药物(卡铂或顺铂)联合治疗广泛期小细胞肺癌(ES-SCLC)患者。SCLC是一种高度侵袭性、快速增长的肺癌,尽管对化疗有应答,但易复发且进展迅速。

Imfinzi是人源化的单克隆抗体,可与PD-L1结合并阻断PD-L1与PD-1和CD80的相互作用,从而对抗肿瘤的免疫逃避并释放对免疫反应的抑制作用。

图片来源:https://www.elsevier.es/en-revista-porto-biomedical-journal-445-articulo-the-pd-1pd-l1-immune-inhibitory-checkpoint-S2444866416000052

此次批准是基于CASPIAN III期试验的阳性结果,结果显示Imfinzi联合化疗与单纯化疗相比,在总体生存率(OS)方面具有统计学和临床意义的改善。

与单独化疗相比,Imfinzi联合化疗将死亡风险降低了27%,中位OS​​为13.0个月,而单纯化疗为10.3个月。结果还显示,Imfinzi联合化疗的客观应答率增加到68%,而单独化疗为58%。相关结果发表在2019 年的Lancet杂志上。

图片来源:Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939.

原始出处:

https://www.firstwordpharma.com/node/1751105?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
    2020-08-24 smartjoy
  3. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
    2020-08-24 swallow
  6. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
    2020-08-23 ms7000000689223974

    讲的很详细,很有用,赞一个

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
    2020-08-23 ms7000000860201024

    ¯\_(ツ)_/¯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=814226, encodeId=f03281422616, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:43:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294567, encodeId=f1b1129456e5a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416497, encodeId=d8b2141649edd, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13925, encryptionId=b1e81392524, topicName=PD-L1单抗Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80615636733, createdName=lidong42, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13924, encryptionId=349913924d1, topicName=PD-L1单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195c13086613, createdName=ylz8407, createdTime=Mon Aug 24 07:00:20 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812511, encodeId=ab76812511c0, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:05:56 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812426, encodeId=ff3d8124261a, content=¯\_(ツ)_/¯, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82815412773, createdName=ms7000000860201024, createdTime=Sun Aug 23 14:43:48 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812383, encodeId=6cc881238370, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:02:43 CST 2020, time=2020-08-23, status=1, ipAttribution=)]
    2020-08-23 ms7000000689223974

    很有用,很不错,谢谢分享

    0

相关资讯

转移性小细胞肺癌(SCLC)新药Zepzelca(lurbinectin)已获批准

制药公司Jazz表示,FDA已批准Zepzelca(lurbinectin)治疗转移性小细胞肺癌(SCLC)患者。

Chest:从不吸烟小细胞肺癌患者的临床和基因组学特征

与吸烟者相比,从不吸烟的SCLC患者具有独特的生物学特性。

Lancet Oncol:Lurbinectedin二线治疗小细胞肺癌

Lurbinectedin作为小细胞肺癌患者铂化疗失败后的二线选择

J Bone Oncol:诊断时有骨转移的小细胞肺癌患者的临床结局

小细胞肺癌(SCLC)患者初诊时有骨转移的小细胞肺癌(SCLC)患者的特点和预后因素几乎没有报道。本研究旨在分析这些患者的预后因素,建立生存评分系统,为临床治疗决策提供依据。

程颖教授谈小细胞肺癌治疗进展和发展趋势

随着研究的进展,人们对小细胞肺癌的认识不断深入,小细胞肺癌分子分型初步形成,每种亚型的小细胞肺癌的发生发展机制的理解,微环境特征的全面揭示,小细胞肺癌也在朝向分型而治发展。

NEJM:肺癌治疗进展对死亡率的影响

2013-2016年,美国非小细胞肺癌患者的死亡率大幅下降,存活率大幅提高。随着治疗进展,发病率的降低,特别是靶向治疗的广泛使用是非小细胞肺癌患者死亡率下降的重要因素

Baidu
map
Baidu
map
Baidu
map